Osteosarcoma is an aggressive bone cancer characterized by high rate of recurrence and metastasis. In a new study, ...

A team of engineers at the University of Florida has developed a new form of CRISPR technology that could make diagnostics ...

The new CRISPR platform, called ΨDNA, reprograms Cas12 nucleases to recognize and act on RNA using a DNA-based guide scaffold ...

WVE-006 generated wild-type M-AAT comprising 64% of total AAT and reduced harmful Z-AAT by 71%, with 11.9 µM total AAT in the 200 mg biweekly cohort; effects were consistent with 400 mg monthly dosing ...

Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering ...

Emerging research suggests reversible RNA editing mechanisms may influence heart disease biology while opening new avenues for biomarkers and next-generation cardiovascular therapies. Review: RNA ...

Airna, a biotechnology startup developing RNA editing treatments, said Tuesday it raised $155 million in a Series B round that will help propel its lead program in alpha-1 antitrypsin deficiency into ...

AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common conditions, is presenting new preclinical data on its therapeutic candidate AIR-001 ...

Wave Life Sciences (WVE) was not the only developer of RNA editing therapies to show significant stock gains from its historic proof-of-mechanism for its RNA editing platform, shown recently in the ...

Researchers developed ΨDNA, a DNA-based CRISPR guide that allows Cas12 enzymes to target RNA with high specificity while ...

Data reinforce WVE-006's potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with mo ...

A research team led by Rice University’s Yang Gao has uncovered new insights into the molecular mechanisms of ADAR1, a protein that regulates ribonucleic acid (RNA) induced immune responses. Their ...